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In February 2018 the international debate on antidepressant
withdrawal was reignited.1-4 In response to a letter published in
the Times by Davies et al on the benefits and harms of
antidepressants,1 the Royal College of Psychiatrists publicly
stated that, “[for] the vast majority of patients, any unpleasant
symptoms experienced on discontinuing antidepressants have
resolved within two weeks of stopping treatment.”2
To support this claim the college referred to guidelines from
the National Institute for Health and Care Excellence (NICE),
which state that “[withdrawal] symptoms are usually mild and
self-limiting over about 1 week.”5
When Davies et al issued a freedom of information request to
NICE asking for the evidence for its one week claim NICE was
able to provide only two short review articles, neither of which
supports the one week claim, although both cite numerous
sources that contradict it.6
We think that NICE’s current position on antidepressant
withdrawal (first established in 2004) not only was advanced
on insufficient evidence but is now widely countered by
subsequent research. Several studies, using a range of methods,
show that many people experience withdrawal for longer than
one week—for example, for over two weeks in 55% of patients,7
at least six weeks in 40%,8 at least 12 weeks in 25%,9 and one
to 13 weeks in 58%10—with other studies finding mean durations
of 11 days11 and 43 days.12
Examples of longer durations, of more than a year, are reported
in two recent community samples of people experiencing
difficulties with withdrawal—by 38.6% (n=185)13 and for a
mean duration of 90.5 weeks (n=97).14
Systematic reviews of withdrawal also concur, and one of the
largest concludes that withdrawal symptoms “typically ensued
within a few days from discontinuation and lasted a few weeks,
also with gradual tapering. Late onset and/or a longer persistence
of disturbances occurred as well.”15 Another stated that
“[withdrawal reactions] typically occur within a few days from
drug discontinuation and last a few weeks . . . many variations
are possible, including late onset and/or longer persistence of
disturbances.”16
The most recent systematic review, by Davies and Read, also
concluded, on the basis of 14 studies of varied methods, that
around half of users experience withdrawal when trying to stop
or reduce antidepressant treatment, that nearly half of those
experiencing withdrawal (46%) report it as severe, and that
reports of symptoms lasting several months are common in
many recent studies (see examples of duration above).17
That the evidence base contradicts NICE’s official position on
antidepressant withdrawal raises concerns for the substantial
jp.davies@roehampton.ac.uk
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2019;365:l2238 doi: 10.1136/bmj.l2238 (Published 21 May 2019) Page 1 of 2
Letters
LETTERS
 o
n
 20 M
ay 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.l2238 on 20 May 2019. Downloaded from 
number of antidepressant users who will experience withdrawal
for a longer duration than current guidelines recognise.
Assuming that doctors abide by such guidelines, we believe that
many people may have their antidepressant withdrawal
misdiagnosed—for example, as relapse or as a failure to respond
to treatment—with antidepressants being reinstated, switched,
or increased in dose as a result.
These practices, if routinely enacted, would help partly explain
why the average time a person spends taking antidepressants
has doubled in the UK since the guidelines were introduced in
2004,18 19 why antidepressant prescriptions are rising overall,
and why patients regularly report that their withdrawal is not
properly acknowledged, understood, and managed by doctors.20 21
In addition, the pooled results of two recent surveys showed
that under 2% of around 3000 patients were able to recall being
told anything about withdrawal effects, dependence, or potential
difficulties in discontinuing treatment.22 23
It is worrying that antidepressants are causing withdrawal effects
that can be long lasting and severe and that this is not being
sufficiently recognised by current clinical guidelines—and, by
extension, many prescribers. NICE is now in the process of
updating its depression guidelines, and we call on it and the
royal colleges to revise their practice guidelines and
recommendations to bring them in line with the scientific
evidence base.
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